Formulated Methylene Blue
Phase 3Small molecule
Formulated Methylene Blue is one of 78 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
279 competitors in Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Tecentriq
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Libtayo
RegeneronPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Vectibix
AmgenPhase 3
Beyfortus
BeiGenePhase 3
Gilotrif
Boehringer IngelheimPhase 3
Tarceva
DDutch Society of Physicians for Pulmonology and Tuberculosis
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Basal Cell Carcinoma1 trial
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
Enrolling by invitation·—·Phase 3·NCT07311070·20 enrolled
Squamous Cell Carcinoma1 trial
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
Enrolling by invitation·—·Phase 3·NCT07311057·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Formulated Methylene Blue. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDaryoush Hamidi Alamdari, PhD